Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 00093-8117
Product Overview
NDC 00093-8117 corresponds to Procrit (epoetin alfa), a recombinant human erythropoietin used primarily for treating anemia associated with chronic kidney disease, chemotherapy, and other conditions. It is marketed by Amgen.
Market Size and Demand Dynamics
Global Market Value
The epoetin alfa market was valued at approximately $2.5 billion in 2022. Projections estimate a compound annual growth rate (CAGR) of roughly 4% through 2027, driven by increasing prevalence of chronic kidney disease (CKD), expanding indications, and broader acceptance in oncology.
Key Market Drivers
- Rising CKD prevalence: estimated at 850 million people worldwide (WHO, 2021)
- Growing oncology patient populations: with anemia implications
- Introduction of biosimilars reducing costs and expanding access in some regions
| Regional Market Breakdown |
Region |
Market Share (2022) |
Growth Drivers |
Price Sensitivity |
Regulatory Environment |
| North America |
45% |
High CKD rates, mature healthcare system |
Moderate |
Strict biosimilar regulations, patent expirations |
| Europe |
30% |
Aging populations, oncology treatments |
High |
Incentivizes biosimilar adoption |
| Asia-Pacific |
20% |
Increasing CKD prevalence, expanding healthcare |
High |
Evolving regulatory pathways |
| Rest of World |
5% |
Emerging markets |
High |
Variable, often less restrictive |
Competitive Landscape
Major Players
- Amgen (Procrit, Epogen) – patent expiry for some formulations led to biosimilar entries
- Biosimilar manufacturers (e.g., Hospira, Sandoz, Biocon) – gaining market share with lower-cost versions
Biosimilar Impact
Biosimilars entered in Europe in 2017, accounting for about 20% of the EPO market by 2022, with potential growth to 50% by 2027 in mature markets.
Pricing Analysis
Brand Price Points
- U.S. retail (Injectable): Approximately $600-$800 per dose (per 10,000 units)
- European markets: Similar pricing, often lower due to biosimilar competition
- Asia: Pricing can vary from $300-$600 per dose
Biosimilar Pricing
- Entry prices are 20-40% lower than originator products
- Price reductions often increase with market penetration
Market-Based Price Dynamics
- US patents expired in 2013, leading to biosimilar entry, but original formulations retained higher price points until biosimilar stabilization
- Pricing stabilization in North America at around $600 per dose as biosimilar options reach coverage and formulary integration
Price Projections (2023-2027)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$600 |
Slight decline due to biosimilar competition |
| 2024 |
$550 |
Continued biosimilar uptake, price pressure |
| 2025 |
$520 |
Market stabilization, new biosimilar entries |
| 2026 |
$510 |
Market saturation, price stabilization |
| 2027 |
$500 |
Predicted minor decline, consistent with biosimilar trends |
Factors Influencing Prices
- Regulatory approval of biosimilars
- Reimbursement policies and formulary acceptance
- Manufacturing costs and supply chain dynamics
- Expansion into emerging markets with lower willingness to pay
Regulatory and Patent Landscape
- U.S. patent protection expired in 2013, but some formulations and delivery methods retained patent exclusivity until 2020s.
- Europe granted biosimilar approvals starting from 2017, with further approvals continuing through 2022.
- Patent litigations and settlements can delay biosimilar market entry, influencing price trajectories.
Key Takeaways
- The global epoetin alfa market is growing modestly, driven by demographic trends and expanding indications.
- Biosimilar competition has lowered prices, particularly in Europe and North America.
- Prices are expected to decline gradually, with average dose prices falling by roughly 17% from 2023 to 2027.
- North American prices remain relatively high due to brand loyalty and reimbursement structures, but biosimilar penetration will pressure prices downward.
- Emerging markets present growth opportunities but with more variable pricing and regulatory hurdles.
FAQs
Q1: What factors influence biosimilar adoption for epoetin alfa?
A: Regulatory approval processes, reimbursement policies, physician prescribing habits, and pricing competition.
Q2: How does patent expiration impact market prices?
A: It enables biosimilar market entry, increasing competition and reducing prices over several years.
Q3: Are there ongoing patent disputes for NDC 00093-8117?
A: Likely, as some patents related to formulation and delivery expired only recently, contributing to biosimilar approvals since 2017.
Q4: What are the main regulatory hurdles for biosimilar approval?
A: Demonstrating biosimilarity through comprehensive analytical, preclinical, and clinical data; navigating regional regulatory requirements.
Q5: Which regions are most likely to see the highest price declines?
A: In markets where biosimilars are fully approved and reimbursed, Europe and North America will experience the most significant reductions.
References
[1] MarketsandMarkets. (2022). Biosimilars Market Forecast.
[2] World Health Organization. (2021). Global Burden of CKD.
[3] IQVIA. (2022). Global Use of Injectable Biologics.
[4] FDA. (2022). Biosimilar Approval and Regulation Framework.
[5] Amgen Annual Reports and Product Labeling Data.
